Business Wire

Money20/20 and FXC Intelligence Release Landmark Report on the Future of European Cross-Border Payments

4.6.2025 12:33:00 CEST | Business Wire | Press Release

Share

Money20/20, the world’s leading fintech show and the place where money does business, has in collaboration with FXC Intelligence, the foremost provider of cross-border payments data and insights, officially launched their joint report How Will Europe’s Money Move in the Future? 2025’s View of 2035.” today at Money20/20 Europe in Amsterdam.

The report delivers a forward-looking, data-driven analysis of how Europe’s cross-border payments ecosystem is set to transform over the next decade. Based on proprietary data and interviews with over 50 European fintech leaders, the report identifies the technologies, regulatory trends, and market shifts expected to reshape Europe’s financial infrastructure by 2035.

The launch took place on the opening day of Money20/20 Europe, where hundreds of industry leaders, regulators, startups and innovators gathered to take part in the report’s findings and engage in conversation about the future of money movement.

Key Findings:

  • Industry Priorities: 83% of leaders prioritize reducing transaction costs, while 82% focus on real-time payments expansion
  • Technology Drivers: Real-time payments and digital wallets emerge as key transformation catalysts
  • Market Leaders: UK, France, Germany, Netherlands, and Estonia lead innovation, with Wise (45%) and Revolut (37%) at the forefront
  • Growth Outlook: Despite US tariffs potentially reducing projections by $1.2 trillion, sector growth remains strong

“Europe is at the tipping point of a new era in money movement,” said Scarlett Sieber, Chief Strategy and Growth Officer at Money20/20. “This report captures the scale of transformation underway—from real-time payments to digital wallets—and the essential role that collaboration between fintechs, regulators, and legacy institutions will play in shaping what comes next.”

The report reveals that 94% of industry leaders expect Europe's cross-border payment infrastructure to transform significantly by 2035. Currently dominating with 46% of global retail cross-border payments, EMEA's outbound flows are projected to reach $25.9 trillion by 2032.

The report highlights five critical priorities:

  1. Reducing transaction costs (83%)
  2. Expanding real-time payments (82%)
  3. Increasing payment speeds (74%)
  4. Integrating digital wallets (73%)
  5. Enhancing transparency (70%)

“This report shows that change in Europe’s payments landscape will be profound yet deliberate,” said Daniel Webber, CEO and Founder of FXC Intelligence.

“Europe’s ability to harmonize regulatory leadership with innovation gives it a powerful edge as it builds the next chapter of global payments.”

About the report

The white paper is the second in a global series from Money20/20 and FXC Intelligence examining the evolution of cross-border payments infrastructure. Following the Asia edition released in April this year, the Europe-focused report offers a regional deep dive that also contributes to a broader global view of money movement trends.

The full report is available HERE

View source version on businesswire.com: https://www.businesswire.com/news/home/20250604417755/en/

Contacts

For more information please contact:
TIna Loncaric
Global Head of PR
Money20/20
tina@money2020.com
M:+ 1 469 288 5556

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye